However, this attempt failed and this approach did not prove successful until the introduction of the incretin hormone glucagon-like peptide-1 (GLP-1) as the basis for glucose-lowering therapeutics in type 2 diabetes
This dual mechanism helps in lowering calorie consumption and aids in weight loss
When used for the purpose for which they were developed, GLP-1 drugs could significantly reduce the cost of care for end-stage kidney disease
As an anti-oxidant, it fosters liver health, strengthen skin elasticity, improve sleep quality, flatten uneven skin tone, maintain skin firmness and elasticity
Meanwhile, FDA approved it in weight reduction for diabetics, diabesity, in 2021
Not knowing what to realistically expect from the medication Why it happens Advertising often implies dramatic, effortless loss, while the phase 3 STEP trials showed semaglutide 2.4 mg produced an average reduction of about 15 to 17 percent over 68 weeks versus placebo, used alongside diet and exercise